-
EP2642999
European procedure
Extract from the Register of European Patents
EP About this file: EP2642999
| EP2642999 - METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 04.08.2017 Database last updated on 22.08.2024 | Most recent event Tooltip | 18.08.2017 | Lapse of the patent in a contracting state | published on 20.09.2017 [2017/38] | Applicant(s) | For all designated states AbbVie Ireland Unlimited Company 70 Sir John Rogerson's Quay Dublin 2 / IE | [2016/44] |
| Former [2015/11] | For all designated states AbbVie Bahamas Ltd. Sassoon House Shirley Street & Victoria Avenue New Providence, Nassau / BS | ||
| Former [2013/40] | For all designated states AbbVie Inc. 1 North Waukegan Road North Chicago, IL 60064 / US | Inventor(s) | 01 /
ELMORE, Steven 2139 Ash Lane Northbrook, Illinois 60062 / US | 02 /
SOUERS, Andrew 901 Hinman Apt. 3a Evanston, Illinois 60202 / US | 03 /
WANG, Li Chun 177 Old Westboro Road North Grafton, Massachusetts 01581 / US | 04 /
GHAYUR, Tariq 1014 Washington Street Holliston, Massachusetts 01746 / US | 05 /
PERPER, Stuart J. 10 Partridge Trail Bellingham, Massachusetts 02019 / US | [2013/40] | Representative(s) | Modiano, Micaela Nadia, et al Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11 80538 München / DE | [2016/39] |
| Former [2013/40] | Modiano, Micaela Nadia, et al Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11 80538 München / DE | Application number, filing date | 11793928.0 | 22.11.2011 | [2016/39] | WO2011US61769 | Priority number, date | US20100416689P | 23.11.2010 Original published format: US 416689 P | [2013/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012071374 | Date: | 31.05.2012 | Language: | EN | [2012/22] | Type: | A1 Application with search report | No.: | EP2642999 | Date: | 02.10.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 31.05.2012 takes the place of the publication of the European patent application. | [2013/40] | Type: | B1 Patent specification | No.: | EP2642999 | Date: | 28.09.2016 | Language: | EN | [2016/39] | Search report(s) | International search report - published on: | EP | 31.05.2012 | Classification | IPC: | A61K31/496, A61P37/00 | [2013/40] | CPC: |
A61K31/5377 (EP,CN,IL,KR,US);
A61K31/496 (EP,CN,IL,KR,US);
A61K45/06 (CN);
A61P1/00 (EP);
A61P13/12 (EP,KR);
A61P27/02 (EP);
A61P37/00 (EP,KR);
A61P37/02 (EP);
A61P37/06 (EP);
A61P43/00 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/40] | Extension states | BA | 30.05.2013 | ME | 30.05.2013 | Title | German: | BEHANDLUNGSVERFAHREN UNTER VERWENDUNG SELEKTIVER BCL-2-INHIBITOREN | [2013/40] | English: | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | [2013/40] | French: | PROCÉDÉS DE TRAITEMENT UTILISANT DES INHIBITEURS SÉLECTIFS DE BCL-2 | [2013/40] | Entry into regional phase | 30.05.2013 | National basic fee paid | 30.05.2013 | Designation fee(s) paid | 30.05.2013 | Examination fee paid | Examination procedure | 30.05.2013 | Examination requested [2013/40] | 10.01.2014 | Amendment by applicant (claims and/or description) | 24.11.2015 | Despatch of a communication from the examining division (Time limit: M02) | 26.01.2016 | Reply to a communication from the examining division | 12.04.2016 | Communication of intention to grant the patent | 11.08.2016 | Fee for grant paid | 11.08.2016 | Fee for publishing/printing paid | 11.08.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | EP16153335.1 / EP3028702 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 24.11.2015 | Opposition(s) | 29.06.2017 | No opposition filed within time limit [2017/36] | Fees paid | Renewal fee | 07.11.2013 | Renewal fee patent year 03 | 07.11.2014 | Renewal fee patent year 04 | 06.11.2015 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 28.09.2016 | [2017/38] | Cited in | International search | [X]WO2009045464 (UNIV JOHNS HOPKINS [US], et al) [X] 1 * title * * claims *; | [X]WO2010065824 (ABBOTT LAB [US], et al) [X] 1-12 * page 185, line 4 - line 6 * * page 207, line 1 - page 210, line 16 * * page 209, line 31 * * page 210, line 4 * * page 448 - page 450; example 296 *; | [XP]US2010298321 (BRUNCKO MILAN [US], et al) [XP] 1-12 * page 215; example 442 * * paragraph [2309] * * paragraph [2402] *; | [A] - GUO ZAIPEI ET AL, "Relationship between the expression of bcl - 2, Fas/Fasl and the apoptosis of peripheral lymphocytes in patients with systemic lupus erythematosus", ZHONGHUA PIFUKE ZAZHI - CHINESE JOURNAL OF DERMATOLOGY, ZHONGGUO YIXUE KEXUEYUAN PIFUBING YANJIUSUO, NANJING, CN, (20010201), vol. 34, no. 1, ISSN 0412-4030, pages 25 - 27, XP009156043 [A] 1-12 * abstract * | [A] - XIE MIN ET AL, Apoptosis and Fas/bcl-2 expression in peripheral blood lymphocytes of patients with systemic lupus erythematosus, CHINESE MEDICAL JOURNAL / ZHONGHUA YIXUE ZAZHI YINGWEN BAN, CHINESE MEDICAL ASSOCIATION, BEIJING, CN, PAGE(S) 1072, (19991201), ISSN 0366-6999, XP009155811 [A] 1-12 * the whole document * | by applicant | WO9507271 | WO9710223 | WO9729131 | WO2005024636 | WO2005049593 | WO2005099353 | WO2006008754 | US2009082471 | US7511013 | US2009088416 | US7514068 | US2009093422 | US7521421 | US2009105338 | US2009105307 | US2009105147 | US2009111840 | US7528131 | US2009118238 | US7531685 | US7534814 | US2009131485 | US2009131363 | US7538189 | US2009137457 | WO2010138588 | - CURRENT ALLERGY AND ASTHMA REPORTS, (2003), vol. 3, pages 378 - 384 | - BRITISH JOURNAL OF HAEMATOLOGY, (2000), vol. 110, no. 3, pages 584 - 90 | - BLOOD, (2000), vol. 95, no. 4, pages 1283 - 92 | - NEW ENGLAND JOURNAL OF MEDICINE, (2004), vol. 351, no. 14, pages 1409 - 1418 | - C. D. JONES; M. KASELJ; R. N. SALVATORE; W. J. LE NOBLE, J. ORG. CHEM., (1998), vol. 63, pages 2758 - 2760 | - "IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry", PURE APPL. CHEM., (1976), vol. 45, pages 13 - 10 | - LIZONDO, J ET AL., DRUGS FUT, (1996), vol. 21, no. 11, page 1116 | - BRICKNER, S J ET AL., J MED CHEM, (1996), vol. 39, no. 3, page 673 | - MALLESHAM, B ET AL., ORG LETT, (2003), vol. 5, no. 7, page 963 | - BLAKE ET AL., J. PHARM. SCI., (1975), vol. 64, no. 3, pages 367 - 391 | - FOSTER ET AL., Advances in Drug Research, ACADEMIC PRESS, (1985), vol. 14, pages 2 - 36 | - KATO ET AL., J. LABELLED COMP. RADIOPHARMACEUT., (1995), vol. 36, no. 10, pages 927 - 932 | - KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., (1999), vol. 77, pages 79 - 88 | - CZAJKA D M; FINKEL A J, ANN. N.Y. ACAD. SCI., (1960), vol. 84, page 770 | - THOMSON J F, ANN. NEW YORK ACAD. SCI, (1960), vol. 84, page 736 | - CZAKJA D M ET AL., AM. J. PHYSIOL., (1961), vol. 201, page 357 | - BLAGOJEVIC N ET AL., Dosimetry & Treatment Planning for Neutron Capture Therapy, ADVANCED MEDICAL PUBLISHING, (1994), pages 125 - 134 | - DIABETES METAB., (1997), vol. 23, page 251 | - ANDREJUS KOROLKOVAS'S, Essentials of Medicinal Chemistry, JOHN WILEY-INTERSCIENCE PUBLICATIONS, (1988), pages 97 - 118 | - DUROCHER ET AL., NUCLEIC ACIDS RESEARCH, (2002), vol. 30, no. 2 | - MIZUSHIMA, S.; NAGATA, S., NUCLEIC ACIDS RESEARCH, (1990), vol. 18, no. 17 | - MARQUINA, REGINA ET AL., JOURNAL OF IMMUNOLOGY, (2004), vol. 172, no. 11, pages 7177 - 7185 | - MASON, K.D. ET AL., "Programmed anuclear cell death delimits platelet life span", CELL, (2007), vol. 128, no. 6, pages 1173 - 86 | - LIU, K.; C. MOHAN, "What do mouse models teach us about human SLE?", CLIN IMMUNOL, (2006), vol. 119, no. 2, doi:doi:10.1016/j.clim.2006.01.014, pages 123 - 30, XP024911762 DOI: http://dx.doi.org/10.1016/j.clim.2006.01.014 | - GELFAND, M.C.; A.D. STEINBERG, "Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone", ARTHRITIS RHEUM, (1972), vol. 15, no. 3, pages 247 - 52 | - RAMOS, M.A. ET AL., "Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice", NEPHROL DIAL TRANSPLANT, (2003), vol. 18, no. 5, pages 878 - 83 | - KWOK, S.K. ET AL., "Dysfunctional interferon-alpha production by peripheral plasmacytoid dendritic cells upon Toll- like receptor-9 stimulation in patients with systemic lupus erythematosus", ARTHRITIS RES THER, (2008), vol. 10, no. 2, page R29, XP021041196 | - RONG, Z. ET AL., "Effect of Interferon-alpha in systemic lupus erythematosus (SLE) serum on the differentiation and maturation of dendritic cells derived from CD34+ hematopoietic precursor cells", JOURNAL OF NANJING MEDICAL UNIVERSITY, (2009), vol. 23, no. 6, pages 380 - 385, XP026793555 | - WILSON, L.E. ET AL., "Autoimmune disease complicating antiviral therapy for hepatitis C virus infection", SEMIN ARTHRITIS RHEUM, (2002), vol. 32, no. 3, pages 163 - 73 | - BARDWELL, P.D. ET AL., "The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity", J IMMUNOL, (2009), vol. 182, no. 12, pages 7482 - 9 | - MATHIAN, A. ET AL., "IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) Fl but not in BALB/c mice", J IMMUNOL, (2005), vol. 174, no. 5, pages 2499 - 506 | - FAIRHURST, A.M. ET AL., "Systemic IFN-alpha drives kidney nephritis in B6.Sle12.3 mice", EUR J IMMUNOL., (2008), vol. 38, no. 7, pages 1948 - 60 | - KAYAGAKI, N. ET AL., "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2", IMMUNITY, (2002), vol. 17, no. 4, doi:doi:10.1016/S1074-7613(02)00425-9, pages 515 - 24, XP002321480 DOI: http://dx.doi.org/10.1016/S1074-7613(02)00425-9 | US20070988479 | US20070941196 | US20080021282 | US20090631404 | US20090631367 | US20100787682 | US20100793418 | US20100793413 |